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Abstract
It was believed that tumors originated from the trans-
formation of their tissue-specific stem cells. However,
bone marrow–derived cells (BMDCs), which possess
an unexpected degree of plasticity and often reside in
other tissues,might also represent a potential source of
malignancy. To study whether BMDCs play a role in the
source of other tumors, BMDCs frommice were treated
with 3-methycholanthrene until malignant transfor-
mation was achieved. Here we show that transformed
BMDCs could form many tumor types, including epi-
thelial tumors, neural tumors, muscular tumors, tumors
of fibroblasts, blood vessel endothelial tumors, and
tumors of poor differentiation in vivo. Moreover, a
single transformed BMDC has the ability to self-renew,
differentiate spontaneously into various types of
tumor cells in vitro, express markers associated with
multipotency, and form teratoma in vivo. These data
suggest that multipotent cancer stem cells seemed to
originate from transformed BMDCs. Conclusively,
these findings reveal that BMDCs might be a source of
many tumor types, even teratoma. In addition, multi-
potent cancer stem cells might originate from malig-
nant transformed BMDCs.
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Introduction
It was believed that tumors originated from the transforma-
tion of their tissue-specific stem cells. The discovery of
multipotent progenitor cells with the capacity for self-renewal
(stem cells) outside the hematopoietic system raises the
possibility that cancer stem cells could arise from other
tissue stem cells and initiate other cancer types, including
solid cancers [1]. Experimental evidence regarding tissue-
specific stem cells contributing to tumors other than the
tissue of origin did not exist until Houghton et al. [2] found
that gastric cancers could originate from bone marrow–
derived sources and indicated that mesenchymal stem cell
(MSC) was the most likely candidate. However, it remained
unclear whether cancer types, except for gastric cancer, could
arise from other tissue stem cells. Recent studies [3,4] have
indicated that MSCs in the bone marrow can be transformed
into cancer cells. In addition, bone marrow–derived cells
(BMDCs), which possess an unexpected degree of plasticity
and often reside in other tissues [5–7], might also represent a
potential source of malignancy. Therefore, we hypothesized
that BMDCs were likely to be a source of many tumor types.
To study this hypothesis, we treated BMDCs with 3-
methycholanthrene (MCA), a potent carcinogen, to derive
transformed BMDCs. Then we studied the characteristics of
tumorigenesis, and the morphology and differentiation of trans-
formed BMDCs. We found that transformed BMDCs could give
rise to different tumor types in vitro and in vivo. Our findings
further support the idea that tumors can originate from trans-
formed BMDCs.
Materials and Methods
Isolation and Culture of BMDCs from the Bone Marrow of Mice
Bone marrow was isolated from the leg bones of 3- to 4-
week-old mice (male Kuming mouse). BMDCs were isolated by
culturing whole marrow in knockout Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) containing
10% fetal bovine serum (FBS; PAA Laboratory, Linz, Austria)
and 1% L-glutamine for 2 days, discarding nonadherent cells
and retaining adherent cells as BMDCs [7]. BMDCs were
selected by their plastic adherence and rapid proliferation.
When cultures reached confluence, the medium was changed
to DMEM (Invitrogen), with low glucose containing 10% FBS.
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Induction of BMDCs Treated with MCA
Primary BMDCs were cultured for 6 to 8 days in DMEM
containing 10% FBS and 1% L-glutamine. Secondary pas-
sages were randomly divided into two groups. One group of
secondary BMDCs was treated with 1 mg/ml MCA (Sigma,
St. Louis, MO) in culture medium (DMEM containing 20%
FBS and 1% L-glutamine) for a week. The medium was
changed twice weekly. MCA was dissolved in dimethyl sulf-
oxide (DMSO; Sigma) to yield a stock solution of 200 mg/ml,
which was stored in the dark at 4jC [8]. It was added to the
medium so that the final concentration of DMSO was 0.5%.
The other group was treated with 0.5% DMSO as control.
Test of Malignant Transformation
Transformed cells were tested for malignancy by the
examination of piled-up colonies on an inverted microscope
stained with Giemsa. The piled-up colonies of transformed
cells heavily were stained with Giemsa, whereas control cells
remained as monolayers and were lightly stained. About
4000 cells were added to a semisolid medium containing
2.7% methyl cellulose (Sigma), DMEM, and 10% FBS. After
8 weeks, the colonies with 16 cells or more were counted.
One hundred of thousands of transformed cells were
injected subcutaneously into 4-week-old immune-deficient
mice (female nude mice). Some mice were injected with
control BMDCs pretreated with DMSO only. Most tumors
appeared in the mice within 8 weeks. Two of these primary
tumors were excised from the mice and injected into sec-
ondary mice.
Tissue Collection and Analysis
Mice were killed at 6 to 8 weeks. The tumors were
removed and fixed in 10% neutral-buffered formalin for
24 hours, then embedded in paraffin wax for analysis. Tumors
were sectioned at 4 mm thickness and were stained using
routine hematoxylin and eosin (H&E).
Fluorescence In Situ Hybridization (FISH)
To identify donor cells in a recipient mouse, in situ hybrid-
ization was performed on a tissue section for the detection of
the Y chromosome, following the manufacturer’s protocol. In
brief, the tissue section was treated with alcohol at 65jC for
1 hour and digested with 200 mg/ml proteinase K. The section
was quenched with protease and dehydrated through graded
alcohols before air drying. The section was denatured by in-
cubating in a denaturation solution at 85jC for 5 minutes,
dehydrated with graded alcohols, and dried at room tem-
perature. A fluorescein isothiocyanate (FITC)– labeled Y-
chromosome paint (star-FISH; Cambio, Cambridge, UK)
was used in the supplier’s hybridization mix. A probe mixture
was incubated at 65jC for 10minutes and held for 30minutes
at 37jC before being added to the section, and then incu-
bated overnight at 37jC. The section was washed with 2
standard saline citrate (SSC) containing 50% formamide
then washed with 1 SSC. Sections were counterstained
with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) before
viewing. The hepatic tissue of a female mouse was used as
a negative control.
Histology and Immunohistochemistry (IHC)
IHC was performed in combination with various immuno-
stains to identify tumor types. Immunocytochemistry was
carried out using standard protocol. Primary antibodies
were diluted as follows: vimentin (Vim, 7 mg/ml; Chemicon,
Temecula, CA), desmin (Des, 1:150; Chemicon), a-smooth
muscle actin (a-SMA, 5 mg/ml; Chemicon), pan-cytokeratin
(pan-CK, 1:400; Sigma), epithelial membrane antigen (EMA,
clone MH1, 1:200; Lab Vision, Fremont, CA), S-100 (1:120;
Chemicon), microtubule-associated protein-2a + b (Map2a +
b, 1:100; Chemicon), neurofilament (NF), glial fibrillary acidic
protein (GFAP, 1:100; Zymed, San Francisco, CA), von
Willebrand factor (vWF, 1:400; Abcam, Cambridge, UK),
and neuron-specific enolase (NSE, 1:200; Dako). Immuno-
detection was performed using SP kit (Zymed). The counter-
stain of preference for nuclear details was hematoxylin.
Isolation of a Single Cell
Transformed BMDCs were serially diluted into an ex-
pansion medium in 96-well plates so that only a single cell
was expanded.
Indirect Cytoimmunofluorescence
Transformed BMDCs from the colony of single cells were
plated at 5  104 cells/well and grown on coverslips (placed
at the bottom of the well) overnight, fixed with acetone, and
incubated with various primary antibodies for 1 hour at room
temperature. Primary antibodies included the following:
Des (1:150; Chemicon), a-SMA (5 mg/ml; Chemicon), vWF
(1:400; Abcam), pan-CK (1:500; Sigma), GFAP (1:100;
Zymed), NF (1:100; Sigma), Vim (7 mg/ml; Chemicon), and
Map2a + b (1:100; Chemicon). Secondary goat anti-mouse or
rabbit antibodies conjugated to Cy5 (1:400; Jackson, West
Grove, PA), FITC (1:300; Chemicon), or Cy3 (1:400; Jack-
son) fluorescent dyes were used for detection. Cell nuclei
were stained with DAPI.
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted from cells using TRIzol (Invi-
trogen). Before the synthesis of first-strand cDNA, total RNA
was treatedwith RNase-freeDNase I (Invitrogen) to eliminate
any residual genomic DNA. The mixture of total RNA was
reverse-transcribed using cDNA synthesis kit (Invitrogen).
The cDNA was amplified with forward (cag aag agg atc acc
ttg gg) and reverse (gtg agt gat ctg ctg tag gg) primers to
detect OCT4; with forward (acc tac agc atg tcc tac tcg) and
reverse (ggg cag tgt gcc gtt aat gg) primers to detect SOX2;
and with forward (agg gtc tgc tac tga gat gct ctg) and reverse
(caa cca ctg gtt ttt ctg cca ccg) primers to detect NANOG,
whereas the internal-control detection of b-actin was per-
formed with forward (tcg tcg aca acg gct ccg gca tgt) and
reverse (cca gcc agg tcc aga cgc agg at) primers. In the case
of OCT4, PCR conditions were as follows: 30 cycles of 94jC
for 30 seconds; 60jC for 1 minute; 72jC for 1 minute; final
extension at 72jC for 5 minutes. In the case of SOX2, PCR
conditions were as follows: 28 cycles of 94jC for 30 seconds;
56jC for 1 minute; 72jC for 1 minute; final extension at 72jC
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for 5minutes. In the case of NANOG, PCRconditions were as
follows: 28 cycles of 94jC for 28 seconds; 55jC for 1 minute;
72jC for 1minute; final extension at 72jC for 5minutes. In the
case of b-actin, PCR conditions were as follows: 28 cycles of
94jC for 30 seconds; 62jC for 1 minute; 72jC for 1 minute;
final extension at 72jC for 5 minutes. PCR products were
electrophoresed on a 1.5% agarose gel and visualized by
ethidium bromide staining. Primary BMDCs without treat-
ment were used as negative control.
Results
Phenotypic Characterization of BMDCs
BMDCs were obtained from the bone marrow of 4-week-
old male mice and were isolated based on their plastic
adherence [7]. Hematopoietic stem cells (HSCs) and other
nonadherent cells were removed with changes in the me-
dium. BMDCs displayed a small round, spindle-shaped, or
flat polygonal morphology (Figure 1A).
BMDCs Undergo Malignant Transformation
About 8 weeks after treatment with MCA, the cells dem-
onstrated properties of malignant transformation. The cells
showedmorphologic changes (Figure 1, B–E ), rapid growth,
anchorage independence (Figure 1F ), loss of contact inhibi-
tion (Figure 1, G and H ), and loss of polarity. We also ana-
lyzed the clonal frequency of transformed BMDCs in the
semisolid medium containing 2.7% methyl cellulose and
found that about 18 of 4000 total transformed cells gave rise
to colonies within 8 weeks. To determine tumorigenic ability,
transformed BMDCs were injected subcutaneously into
4-week-old immune-deficient mice (female nude mice) and
formed tumors (Figure 1I ) in 33 of 33 mice. Every mouse
formed tumors in the position of injection of transformed cells.
Most tumors appeared in the mice within 6 weeks. Tissue
sections showed properties of malignant tumors, such as
cellular atypia, tumor giant cells, and pathological mitosis. In
some cases, invasive growth into skeletal muscles and fatty
tissues was observed. Two of these primary tumors were
excised from mice and injected into secondary mice to
examine their ability to self-renew. After 2 weeks, two of two
injections gave rise to tumors. The secondary tumors re-
sembled the original tumors, whereas the group of injected
mice that underwent BMDC treatment with DMSO did not
form tumors until their death.
These findings suggested that transformed cells pos-
sessed all the characteristics of malignant transformed cells,
Figure 1. Detection of malignant transformation. (A) Morphologic characteristics of BMDCs before treatment. (B– I) BMDC treatment with MCA produced
characteristics of malignant transformation. (B–E) Morphologic changes of treated BMDCs (stained with H&E). (B) Cellular and nuclear atypia. (C) Nuclear atypia.
(D) The number of nucleolus increased. (E) Multinuclear giant cell. (F) Treated BMDCs formed piled-up foci (stained with Giemsa). (G and H) Treated BMDCs
formed clones in the semisolid medium containing 2.7% methyl cellulose. (I) Treated BMDCs formed a tumor in the subcutaneous layer. Scale bars: (A) 40 m; (B,
C, E–H) 20 m; (D) 10 m.
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especially the capacity to self-renew and to form tumors.
Therefore, BMDCs transformed into cancer cells. These
results were reproducible. We derived transformed BMDCs
in three independent experiments.
Transformed BMDCs Produce Different Tumor Types
In Vivo
Tumor tissue sections were analyzed by histology and
immunochemistry to identify tumor types. Immunochemically,
the tumors were tested for different tissue-specific markers,
including epithelial, neural, and mesenchymal markers
(Figure W1). Immunochemical results showed that these
tumors expressed different antigen profiles (Table 1). Tumors
expressed markers of mesenchymal tissues (Vim, Des,
a-SMA, and vWF), epithelial tissues (pan-CK and EMA), or
neural tissues (NF, GFAP, S-100, and Map2a + b). Some
tumors contained more than one histologic type of cancer
tissue and expressed markers of different tissues simulta-
neously. There were also tumors that were poorly differenti-
ated and did not express any antigens that had been tested
(Table 1). According to histologic characteristics and immu-
nochemical data (Figure 1), these tumors were divided into
muscular tumors, blood vessel endothelial tumors, tumors of
fibroblasts, epithelial tumors, neural tumors, and tumors of
poor differentiation (Figure 2, A–H ).
Tumorswere identified as donor-derived by the presence of
the Y chromosome in female mice. Tumors from male-to-
female transplants showed Y chromosomes (green) within
the nuclei (blue) (Figure 2, I–L). The results confirmed that
these tumors derived from donor cells of transformed BMDCs.
These results demonstrated that transformed cells pro-
duced various tumor tissue types during the course of tumor
formation. Consequently, our results suggested that trans-
formedBMDCs could give rise to different tumor types in vivo.
Transformed BMDCs Produce Many Types of Tumor
Cells In Vitro
During the routine passage of transformed cells, more
than one cell phenotype were frequently observed in culture.
We studied the differentiation of transformed BMDCs by
testing for tissue-specific markers. The cells stained posi-
tively for antigens of pan-CK, vWF, GFAP, Vim, NF, or Des
(Figure 3). These data showed that transformed BMDCs
differentiated spontaneously into epithelial tumor cells, blood
Table 1. IHC Showing the Expression of Tissue-Specific Markers in Tumors
Expressed in Different Antigen Profiles.
Tumors (n) Vim Des SMA F VIII Pan-CK EMA S-100 GFAP NF Map2
8 + + ±  + ±    
2 +    + ±    
3     + ±    
1 + +  +      
3 + + ±  ±  +  + +
2 +      + + + +
5 + +        
3 +         
6 +         
Figure 2. (A–H) The sections showed different tumor types (stained with H&E). Based on phenotypic characterization and immunochemical analysis, the sections
were divided into different tumor tissue types. (A ) Leiomyoma. (B) Hemangioendothelioma. (C) Fibrosarcoma. (D) Sarcomatoid carcinoma. (E) Epithelial tumor. (F)
Neurilemoma. (G) Mixed tumor of neurocyte and gliacyte. (H) Tumor of poor differentiation. (I –K) FISH-confirmed tumors derived from donor cells (green dot in
nuclei). (I) The Y chromosome (FITC-conjugated; green). (J) DAPI staining of cell nuclei (blue). (K) The overlay of the Y chromosome (green dot) within the nuclei
(blue). (L) The FISH result for the Y chromosome, using the hepatic tissue of the female mouse that was used as control, was negative. Scale bars: (A–F, H)
100 m; (G) 25 m; (I –L) 10 m.
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vessel endothelial tumor cells, glial tumor cells, neuronal
tumor cells, and muscular tumor cells in vitro. Multiple dif-
ferentiations of transformed BMDCs were subjected to stan-
dard culture conditions (DMEM and 10% FBS). Therefore,
transformed BMDCs also possessed the ability to produce
various tumor cells in vitro.
Transformed BMDCs not only could give rise to various
types of tumor cells in vitro but also could undergo in vivo
differentiation to produce many tumors similar to those in
diseases of mouse tumors. Therefore, the findings demon-
strated that various tumor types could originate fromBMDCs.
However, what kind of cells in transformed BMDCs is
associated with the formation of so many tumor types? Many
researches have shown that cancer stem cells, which form
only a small proportion of the total tumor cell population, were
the only tumor cells with the capacity to keep tumors growing
[9–11]. Moreover, the experiments here showed that the
clonal frequency of transformed BMDCs in the semisolid
medium containing 2.7% methyl cellulose was only 18 of
4000. It means that not all transformed BMDCs had the ability
to propagate. Therefore, animal implant and in vitro studies
showed that transformed BMDCs could give rise to multiple
tumor types, suggesting that there were either multipotent
cancer stem cells or mixtures of committed progenitor cells
with restricted potential [12,13] in transformed BMDCs. We
wanted to know whether a multipotent cancer stem cell
presented in transformed cells is responsible for these tumor
types. If it were true that there existed multipotent cancer
stem cells in transformed BMDCs, some single cells should
produce multiple tumor types.
Transformed BMDCs Exhibit Properties of Multiple Cancer
Stem Cells in Culture
Transformed BMDCs were serially diluted into an expan-
sion medium in 96-well plates so that only a single cell was
expanded. Clonal transformed BMDCs were derived from a
single cell.
We found that the cells that expanded from a single cell
showed various phenotypes (Figure 4), as well as expressed
different tissue-specific antigens in vitro (Figure 5). Thus, the
results suggested that a single cell could produce various
types of tumor cells in vitro. In addition, a single cell has been
passaged up to 10 times to date without diminution of its
colony-forming ability. To our interest, some cells can grow as
multicellular spheroids after they had been cultured for about
2 weeks (Figure 4I ). Together, transformed BMDCs at the
single-cell level that possess the ability for self-renewal and
multiple differentiation indicated that multipotent stem cells
seemed to present in transformed BMDCs.
Clonal Transformed BMDCs Express Genes Related
to Multipotency In Vitro
Critical transcription factors, notably OCT4, SOX2, and
NANOG, are necessary to maintain self-renewal and pluri-
potency—two characteristics of embryonic stem (ES) cells
[14,15]. Thus, the expressions of OCT4, SOX2, and NANOG
are specific markers associated with pluripotency and self-
renewal [14,15]. To further analyze the multipotency of clonal
transformed BMDCs, we examined their expression of
OCT4, SOX2, and NANOG. RT-PCR results showed that
clone-transformed BMDCs expressed the genes of OCT4,
SOX2, and NANOG (Figure 6). The expression of three
markers indicated a possible multipotent nature of trans-
formed BMDCs. This finding further supported that some
transformed BMDCs possessed the abilities of self-renewal
and pluripotency in vitro.
Clonal Transformed BMDCs Form Various Tumors In Vivo
To examine whether clonal transformed BMDCs pos-
sessed the ability for self-renewal and pluripotency in vivo,
Figure 3. In vitro– transformed cells from BMDCs were tested for the ability to differentiate into multiple lineages at single-cell level. Cultures were examined with
indirect immunofluorescence confocal microscopy of differentiated cells decorated with antibodies against pan-CK, vWF, Des, NF, GFAP, and Vim. (A) Anti –pan-
CK labeled with Cy5. (B) Anti – vW-Cy3. (C) Anti –Des-Cy3. (D) Anti –Vim-Cy5. (E) Anti –GFAP-Cy3. (F) Anti –NF-Cy5. Scale bar: 10 m.
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clonal transformed BMDCs were injected subcutaneously
into 4-week-old immune-deficient mice (female nude mice)
and formed tumors in five of five mice. Every mouse formed
tumors in the position of injection of the cells. Another five
mice injected primary BMDCs without treatment, and no
tumors were found until the mice had died. Histologic ex-
amination revealed that one of five tumors contained three
germ layers, two contained two germ layers, one contained
neural tumor cells, and one had low differentiation (Table 2).
The tumor containing three germ layers showed properties
typical of teratoma. The teratoma contained the derivatives
of all three germ layers, including muscles, cartilages, kera-
tinocytes, squamous epithelium, glandular epithelium, seba-
ceous glands, tissues of glia, and tissues of neural fibers
(Figure 7; and W2). These findings showed that clonal trans-
formed BMDCs possessed the abilities for self-renewal,
pluripotency, and tumorigenesis. In vivo studies further con-
firmed that some cells in transformed BMDCs functioned as
multiple cancer stem cells.
The three aspects of experiments demonstrated fully that
transformed BMDCs contained multiple cancer stem cells,
which answerswhy transformedBMDCsgave rise to different
tumor types. Therefore, the presence of multiple cancer stem
cells further supported the hypothesis that BMDCs might be
a source of various tumor types.
Discussion
In the present study, malignant transformed BMDCs were
induced byMCA.Our experiments indicated that transformed
BMDCs could produce various types of tumors in vivo (e.g.,
epithelial tumors, muscular tumors, tumors of fibroblasts,
neural tumors, blood vessel endothelial tumors, tumors of
poor differentiation, mixed tumors, and teratomas). These
results demonstrated that many tumor types could originate
from BMDCs. Houghton et al. [2] found that gastric cancers
can arise from BMDCs. Our experiments were similar to the
findings of Houghton et al. and extended the concept that
tumors could originate from other tissue cells.
The passage of transformed BMDCs produced various
types of tumor cells in vitro and, when inoculated in nude
mice, these cells gave rise to different tumor types in vivo.
Therefore, it was possible that multipotent stem cells that
existed in transformed BMDCs could produce many types of
cancer cells. Of course, it was also possible that there were
populations that were mixtures of committed stem cells, each
Figure 4. Phase-contrast micrographs of a single cell’s derivatives. The single cell produced various tumor cells in a dish. The cells showed different phenotypes in
culture. (A) Neural-like cells. (B) Spindle-shaped cells. (C) Small round cells and spindle-shaped cells. (D) Flat polygonal cells. (E) Flat polygonal cells. (F) Small
round cells, spindle-shaped cells, and epithelial-like cells. (G) Flat polygonal cells. (H) Spheroids of small round cells. (I) Multicellular spheroids formed after a 2-
week culture. Scale bar: 20 m.
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with restricted potential in transformed BMDCs. Our experi-
ments revealed that multipotent stem cells seemed to exist in
transformed BMDCs because transformed BMDCs at the
single-cell level could: 1) self-renew; 2) differentiate into
various types of tumors cells in vitro; 3) express markers
associated with multipotency; and 4) form teratomas contain-
ing three germ layers in vivo. The discovery of multiple cancer
stem cells provided an idea that some tumors containing
multiple germ layers might relate to multiple cancer stem
cells. Although our studies indicated that multipotent cancer
stem cells were present in transformed BMDCs, further
studies in this field will be needed to know fully the charac-
teristics of multiple cancer stem cells.
Teratomas could be derived from transformed BMDCs,
providing evidence of a possible origin of teratomas from
BMDCs. However, teratomas were usually believed to origi-
nate from ES cells. For the first time, we reported that tera-
tomas also could originate from adult cells or adult stem cells.
Figure 5. Marker expression of the differentiated progeny from single transformed BMDCs. (A) Anti –pan-CK labeled with Cy5. (B) Anti –Vim-Cy5. (C) Anti –Des-
Cy3. (D) Anti –SMA-Cy3. (E) Anti –vW-Cy3. (F) Anti –Nestin-Cy3. (G) Anti –GFAP-Cy3. (H) Anti –NF-FITC. (I) Anti –Map2-FITC. Scale bar: 10 m.
Figure 6. RT-PCR analysis of gene expression related to multipotency and
self-renewal in clonal transformed BMDCs. -Actin band, 520 bp; OCT4 band,
324 bp; SOX2 band, 276 bp; and NANOG band, 364 bp. Primary BMDCs were
used as controls.
Table 2. Types of Tumor Produced by Clonal Transformed BMDCs In Vivo.
Tumors
(n)
Type of Tumor
Tissues
Vim Des Pan-CK EMA S-100 GFAP NF Map2
1 Muscular and
epithelial tissues
+ + + +    
1 Epithelial and
neural tissues
+ +   + + + +
1 Three germ layers + + + + + + + +
1 Neural tissues     + + + +
1 Low-differentiation
tissues
       
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The experiments here showed that transformed BMDCs
possessed a multipotent nature and an ability for self-
renewal. These properties may be inherent in BMDCs, rather
than acquired over time, indicating that multipotent cancer
stem cells derived seemingly from some undifferentiated
cells or multipotent progenitor cells. As we know, adult
BMDCs include two populations of bone marrow stem cells:
HSCs andMSCs [16]. First, the cell culture condition we used
was not compatible with HSCs. Second, cultured BMDCs
were identical to MSCs in terms of phenotype [5,7]. In ad-
dition, MSCs have been shown to differentiate into many
different cell lineages [5–7,17,18]. Finally, recent in vitro
studies suggested that adult MSCs might be a target for
neoplastic transformation [3,4]. Hence, MSCs in BMDCs
were the most likely candidates responsible for cancer stem
cells in transformed BMDCs. However, all features of trans-
formed BMDCs did not ascribe to MSCs in BMDCs. The
BMDCs seemed to obtain some properties of embryonic cells
during the course of transformation and long cultures, which
were inherent to some cells in BMDCs, because the primary
BMDCs did not show the same nature in the present experi-
ments. Of course, it was also possible that there were more
immature stem cells in the bone marrow [19] that might
contribute to multiple cancer stem cells.
Cell fusion has recently been suggested as an expla-
nation for stem cell plasticity [20,21]. Our case cannot be
explained by the same mechanism. Because transformed
BMDCs have never been cocultured with tissue-specific cells
or ES cells (which differentiate into cells of three germ
layers), the in vitro multiple differentiation potential of trans-
formed BMDCs cannot be attributed to cell fusion. Moreover,
transformed BMDCs could form teratomas after subcu-
taneous transplantation.
In conclusion, these findings suggest that various tissue
tumors may originate from BMDCs. Multipotent cancer stem
cells were involved in transformed BMDCs, contributing to
various tumor types. For the first time, we show that terato-
mas also can originate from adult cells or adult stem cells.
These concepts will help us to better understand the origin of
tumors and to develop more effective treatments.
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Figure W1. Immunochemical images of tumor sections in Figure 2. (A) IHC for a-SMA (brown stain). (B) Des (brown stain). (C) vWF (brown stain). (D) Vim (brown
stain). (E) Pan-CK (brown stain). (F) Pan-CK (brown stain). (G) EMA (brown stain). (H) S-100 (brown stain). (I) NF (brown stain). (J) NSE (brown stain). (K) GFAP
(brown stain). (L) Map2 (brown stain). (M) Negative section. Scale bars: (A, D, G, M) 50 m; (B, C, E, F, H–L) 100 m.
Figure W2. Immunochemical image of the teratoma. (A) a-SMA. (B) Des. (C) S-100. The cartilage yielded a positive result. (D) Pan-CK. (E) GFAP. (F) NF. (G)
GFAP. (H) Pan-CK. Scale bar: 100 m.
